Skip to main content

Table 5 Immunogenicity and seroconversion rates to measles and rubella components of MMR vaccine currently used in Iran

From: Measles and rubella serosusceptibity among population vaccinated with different schedules: the potential impact on measles-rubella elimination in Iran

Author/province

vaccine brand

Years of study

No of Subjects

Age

Lab method

Responses Rate MMR (%)

MMR1first dose

MMR22second dose

M

R

M

R

Saffar, Mazandaran Razi-Iran [48]

2007

112

12.10 mo

ELISA

84.8%

53%

Saffar, Mazandaran

Razi-Iran [49]

2011

249

228

18 m

6 yr

ELISA

74%

6- mo after MMR1

5- yr after MMR1

78.9%

75%6- mo afetr MMR1

66% 5- year after MMR1

94.4%

92.6%

1- mo after MMR2

98.2

87%

1- mo after MMR2

Shamsizadeh, Ahwaz Karaj-Iran Razi Iran [50]

2010–2011

70

90

18 mo

6.5 yr a

ELISA

6- mo after MMR1

42.9%

-

6- mo after MMR190%

-

-

45.6%

-

87.8%a

Tabatabaei, Razi-Iran [51]

2011–2012

240

13.27 mo [12,13,14,15]

ELISA

75.8%

73.8%

Zahrari, Baluchestan –Kerman-Hormozgan Razi-Iran [36]

2016

236

> 12 mo

ELISA

91.2%b

 

 

Izadi, Baluchestan –Kerman-Hormozgan Razi-Iran [37]

2015

663

30–54 mo

 

94.6%c

  1. a: One dose of MMR vaccine in addition to two doses of MV at the ages nine and 15 months.
  2. b: Based on strict control of the vaccination administration technique and cold chain control by the researchers.
  3. c: Two- doses of MMR at the ages of 12 and 18 months.